MicroRNA expression profile and TNM staging system predict survival in patients with lung adenocarcinoma.

ObjectThe current study was performed to construct a model with microRNA (miRNA/miR) expression profile and TNM staging system for prognosis predicting in patients with lung adenocarcinoma (LUAD). MethodsDifferentially expressed miRNAs were identified from miRNA data of LUAD in The Cancer Genome Atlas (TCGA) database. Potential prognostic miRNAs and TNM classification parameters, screened out by Cox proportional hazards regression analysis, were included in the prognostic model. The prognostic model was visualized with a nomogram, and tested by calculating the C-index and drawing the calibration curve in the training set and validating set, respectively. Finally, the prognostic miRNAs were analyzed with bioinformatics tools. ResultsA total of 194 differentially expressed miRNAs were identified between LUAD tissues and matched normal tissues, including 99 up-regulated and 95 down-regulated miRNAs. miRNA index (miR.index), constructed with nine miRNAs (hsa-let-7i, hsa-mir-1976, hsa-mir-199a-1, hsa-mir-31, hsa-mir-3940, hsa-mir-450a-2, hsa-mir-4677, hsa-mir-548v and hsa-mir-6803), was an independent prognostic indicator for the survival of patients with LUAD. Bioinformatics analysis suggests that the selected miRNAs are involved in the development and progress of LUAD. ConclusionThe prognostic model constructed with nine miRNA expression profile and TNM classification parameters can predict the survival in patients with LUAD, and the predictive power of the model are warranted for further validations.

Application of high resolution pyrolysis gas chromatography/mass spectrometry (HRPGC/MS) for detecting Listeria monocytogenes.

The characteristic of Listeria monocytogenes' pyrolysis product was found by fingerprint analysis of high resolution pyrolysis gas chromatography and mass spectrometry (HRPGC/MS), which hold a great potential to rapidly detect L. monocytogenes with the application of selected ion monitoring (SIM). Food products (beef and milk) contaminated by L. monocytogenes and uncontaminated were evaluated. The retention time of the characteristic peak of pyrolysis product was 19.056min, the ion of m/z were 54, 98. The results showed that the peak at retention time 19.056min was detected in agricultural products that contaminated by L. monocytogenes, while the result of the uncontaminated food, there is no peak at the retention time 19.056min. Qualified by the retention time of chromatographic and mass spectrometry, it can eliminate the interference induced by different types of agricultural products. The results prove united technologies of HRPGC/MS and SIM is not only reliable, reproducible, but also a new method for rapid detecting L. monocytogenes in food products.

Specific detection of Vibrio parahaemolyticus by fluorescence quenching immunoassay based on quantum dots.

In this study, anti-Vibrio parahaemolyticus polyclonal and monoclonal antibodies were prepared through intradermal injection immune and lymphocyte hybridoma technique respectively. CdTe quantum dots (QDs) were synthesized at pH 9.3, 98 °C for 1 h with stabilizer of 2.7:1. The fluorescence intensity was 586.499, and the yield was 62.43%. QD probes were successfully prepared under the optimized conditions of pH 7.4, 37 °C for 1 h, 250 µL of 50 mg/mL EDC · HCl, 150 µL of 4 mg/mL NHS, buffer system of Na2HPO4-citric acid, and 8 µL of 2.48 mg/mL polyclonal antibodies. As gold nanoparticles could quench fluorescence of quantum dots, the concentration of V. parahaemolyticus could be detected through measuring the reduction of fluorescence intensity in immune sandwich reaction composed of quantum dot probe, gold-labeled antibody, and the sample. For pure culture, fluorescence intensity of the system was proportional with logarithm concentration of antigen, and the correlation coefficient was 99.764%. The fluorescence quenching immunoassay based on quantum dots is established for the first time to detect Vibrio parahaemolyticus. This method may be used as rapid testing procedure due to its high simplicity and sensitivity.

A comparative study on the pharmacokinetics of a traditional Chinese herbal preparation with the single herb extracts in rats by LC-MS/MS method.

The Er-Mu preparation (EMP) is a well-known traditional Chinese prescription that has been clinically employed for the treatment of asthma and bronchial inflammation for hundreds of years. Neomangiferin, mangiferin, peimine, peiminine, timosaponin BII and timosaponin AIII are the major active ingredients of EMP for their anti-inflammatory or anti-asthmatic effects. The aim of this study was to investigate the pharmacokinetics of the target compounds from the recipe of EMP and the single herb extracts of Anemarrhenae asphodeloides Bge. (ARR) and Fritillariae cirrhosae D.Don (FCB), and the influence of compatibility on the pharmacokinetics of the main active ingredients. The rats were randomly assigned to three groups and orally administered with the recipe of EMP and the single herb extracts of ARR and FCB, respectively. The concentrations of the target compounds in rat plasma were determined by an optimal liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS) and multiple reaction monitoring (MRM) with a multi-switching monitoring mode coupled with simple protein precipitation method, and the main pharmacokinetic parameters were estimated. Significant differences (p<0.05) were found in the pharmacokinetic parameters of neomangiferin, mangiferin, peimine and peiminine between the single ARR or FCB extract and the combination treatment (p<0.05). The developed HPLC-ESI-MS method by switching positive and negative ESI sources in a single run was successfully applied to study the pharmacokinetics of six compounds in SD rat, which was powerful in terms of sensitivity, selectivity, time savings and solvent consumption in the quantitative analysis of complex herbal medicines. It was surmised that formula compatibility could significantly influence the pharmacokinetics of EMP and our study has preliminarily elucidated the priority in the compatible administration of EMP based on pharmacokinetic studies.